查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957285

Risperidone市場－全球產業規模、佔有率、趨勢、機會、預測：按給藥途徑、應用、最終用戶、地區和競爭對手分類，2021-2031年

Risperidone Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Route Of Administration, By Application, By End-Users, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球Risperidone市場預計將從 2025 年的 63.6 億美元成長到 2031 年的 85.8 億美元，複合年成長率為 5.12%。

Risperidone是一種非典型抗精神病藥物，主要用於治療思覺失調症、躁鬱症和自閉症相關過敏症。精神疾病診斷率的提高和學名藥價格的下降推動了市場穩定，進而促進了全球醫療保健系統對該藥物的廣泛應用。此外，利培酮在穩定成人和兒童患者的急性躁鬱症發作和精神病發作方面的確切療效預計將持續推動市場需求。

市場概覽
預測期 2027-2031
市場規模：2025年 63.6億美元
市場規模：2031年 85.8億美元
複合年成長率：2026-2031年 5.12%
成長最快的細分市場 口服
最大的市場 北美洲

然而，市場成長面臨的主要障礙在於患者的依從性。體重增加和運動障礙等副作用常常會影響患者的依從性。這些安全隱患促使處方醫師越來越傾向於選擇更新、耐受性更好的替代藥物。根據國際藥品製造商協會聯合會（IFPMA）預測，到2024年，全球將有約10億人受到精神疾病的影響。如此龐大的患者群體凸顯了對Risperidone等現有治療方法的迫切需求，即便麵臨來自新型治療方法的激烈競爭。

市場促進因素

全球思覺失調症和雙相情感障礙盛行率的上升是Risperidone全球市場的主要促進因素，這些疾病需要持續的藥物治療來控制慢性症狀。隨著患者人數的增加，醫療保健系統面臨越來越大的壓力，需要確保患者能夠獲得抗精神病藥物治療，以減輕嚴重精神疾病的社會影響。美國藥物濫用和精神健康服務部於2025年7月發布的《2024年全國藥物濫用和健康調查》數據顯示，到2024年，美國約有1460萬成年人患有嚴重精神疾病，這凸顯了對有效治療方案的巨大需求。這種日益加重的疾病負擔與Risperidone等常用抗精神病藥物處方量的增加直接相關。

同時，市場正隨著長效注射劑型的日益普及而不斷發展，旨在提高患者依從性並最大限度地降低因不規律口服給藥而導致的複發率。製藥公司正抓住這轉變機遇，部署能夠提供持續療效的先進給藥系統。例如，Teva製藥在2025年1月發布的2024年第四季及全年財報中指出，其長效Risperidone注射劑Uzedi在2024年的全球銷售額已達到1.17億美元，超出預期。這種向先進製劑的轉變在新興市場也十分明顯，路易製藥集團（Louillet Pharma Group）報告稱，其中樞神經系統產品組合（包括Risperidone微球製劑Likind）在2025年上半年的銷售額成長了5.4%。

市場挑戰

Risperidone市場的擴張直接受到副作用的阻礙，尤其是體重增加和運動功能障礙等安全隱患。這些生理反應往往會降低患者的藥物順從性，並成為持續用藥的一大障礙。當患者出現顯著的代謝變化或不自主肌肉收縮時，他們通常會停止治療或要求調整用藥方案。因此，醫療專業人員被迫尋求耐受性更好的替代療法，導致Risperidone等現有療法的依賴性和市場佔有率下降。

向新一代抗精神病藥物的轉變源自於臨床上持續控制症狀且避免產生嚴重副作用的需求。此疾病的廣泛流行凸顯了這一問題的嚴重性，因為患者需要持續治療。世界衛生組織（WHO）在2024年報告稱，全球約有2400萬人患有思覺失調症，儘管治療的連續性至關重要，但仍有大規模一部分患者因藥物不耐受而中斷治療。因此，更安全的替代藥物的存在限制了Risperidone的獲利能力，因為醫生在處方選擇中越來越重視病人的生活品質和用藥依從性。

市場趨勢

每週一次的口服胃滯留膠囊的研發是一項重要的技術突破，旨在彌合每日口服藥物依從性和侵入性注射療法之間的差距。這種創新製劑採用了一種新型劑型，可滯留在胃中並在七天內持續釋放藥物，從而有效減輕了思覺失調症患者的用藥負擔，而用藥負擔往往是阻礙治療成功的因素。此方法無需注射即可維持穩定的血漿藥物濃度，既解決了用藥依從性問題，也尊重了病人的自主權。根據HMP全球學習網路2025年6月發布的題為「新型長效口服Risperidone製劑在3期臨床試驗中臨床實驗出令人鼓舞的結果」的報導，STARLYNG-1試驗中每週一次的膠囊LYN-005維持了治療濃度，在第5週時，其最低濃度幾何平均比值達到1.04，高於每日一次的速釋Risperidone。

同時，非專利注射劑學名藥的推出正在改變市場競爭格局，為長期使用的品牌微球製劑提供了一種價格更實惠的替代方案。標準長效抗精神病藥物的複雜非專利藥的核准和上市，打破了原廠藥曾經享有的市場壟斷地位，從而顯著降低了價格，並擴大了支付方和患者的用藥範圍。這種轉變迫使品牌藥生產商專注於新的給藥技術，而學名藥則在成熟的注射劑市場中不斷擴大市場佔有率。例如，2025年11月，魯賓公司在其題為《魯賓推出Risperidone緩釋懸浮液非專利藥》的報告中宣布，將在美國推出學名藥，目標市場規模約為1.87億美元。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球Risperidone市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 給藥途徑（注射、口服、腸外給藥）
    • 依病症分類（思覺失調症、躁鬱症、泛自閉症障礙相關的易怒等）
    • 依最終使用者（醫院、居家醫療、專科診所、門診手術中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美Risperidone市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲Risperidone市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：Risperidone在亞太地區的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：Risperidone在中東和非洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：Risperidone在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球Risperidone市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Otsuka Pharmaceutical Co., Ltd
  • AbbVie Inc
  • Dr. Reddy's Laboratories Ltd
  • Pfizer Inc
  • Endo International plc
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Viatris Inc
  • Novartis AG
  • Lupin Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17688

The Global Risperidone Market is projected to expand from USD 6.36 Billion in 2025 to USD 8.58 Billion by 2031, reflecting a CAGR of 5.12%. As an atypical antipsychotic, risperidone is primarily employed in the management of schizophrenia, bipolar disorder, and autism-related irritability. Market stability is largely underpinned by increasing diagnostic rates for psychiatric conditions and the affordability of generic versions, which facilitates widespread access across healthcare systems worldwide. Additionally, the drug's proven effectiveness in stabilizing acute manic or psychotic episodes in both adult and pediatric patients ensures continuing demand.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.36 Billion
Market Size 2031USD 8.58 Billion
CAGR 2026-20315.12%
Fastest Growing SegmentOral
Largest MarketNorth America

However, market growth encounters a substantial hurdle regarding patient adherence, often compromised by adverse reactions such as weight gain and movement disorders. These safety concerns frequently lead prescribers to favor newer generation alternatives that offer improved tolerability. According to the International Federation of Pharmaceutical Manufacturers and Associations, mental health conditions impacted nearly one billion individuals globally in 2024. This extensive patient population underscores the urgent requirement for accessible treatments like risperidone, even amidst strong competitive pressure from novel therapeutic options.

Market Driver

The rising global prevalence of schizophrenia and bipolar disorder serves as a major engine for the Global Risperidone Market, requiring continuous pharmacological support to control chronic symptoms. As patient numbers grow, healthcare systems face increasing pressure to ensure the availability of antipsychotic therapies to alleviate the societal impact of severe psychiatric illnesses. Data from the Substance Abuse and Mental Health Services Administration in July 2025, referencing the '2024 National Survey on Drug Use and Health', indicates that approximately 14.6 million adults in the United States were identified as having a serious mental illness in 2024, highlighting the immense need for effective therapeutic solutions. This growing disease burden correlates directly with higher prescription rates for established antipsychotics such as risperidone.

Simultaneously, the market is evolving through the increased uptake of long-acting injectable formulations aimed at improving patient compliance and minimizing relapse rates linked to inconsistent oral dosing. Pharmaceutical developers are leveraging this shift by launching advanced delivery systems that provide extended-release benefits. For example, Teva Pharmaceutical Industries reported in its January 2025 'Fourth Quarter and Full Year 2024 Financial Results' that global revenue for UZEDY, its extended-release risperidone injectable, hit $117 million in 2024, exceeding initial expectations. This transition toward advanced formulations is also apparent in emerging markets; Luye Pharma Group noted in 2025 that revenue from its central nervous system portfolio, including the risperidone microsphere Rykindo, rose by 5.4% in the first half of the year.

Market Challenge

Expansion of the risperidone market is directly impeded by safety issues involving adverse effects, particularly weight gain and movement disorders. These physical reactions often lead to suboptimal patient compliance, forming a significant obstacle to sustained usage. When patients undergo considerable metabolic shifts or involuntary muscle contractions, they frequently stop treatment or demand adjustments to their medication plans. Consequently, healthcare providers are compelled to explore alternative therapies with better tolerability, thereby diminishing the reliance on and market share of established options like risperidone.

The trend toward newer generation antipsychotics is driven by the clinical necessity to manage symptoms consistently without causing debilitating side effects. The scale of this issue is highlighted by the widespread prevalence of conditions needing ongoing care; the World Health Organization reported in 2024 that schizophrenia affects roughly 24 million people worldwide, a large demographic for whom treatment continuity is vital but often disrupted by drug intolerance. As a result, the existence of safer pharmacological alternatives constrains risperidone's revenue potential, as physicians increasingly emphasize patient quality of life and adherence when making prescribing choices.

Market Trends

The creation of Once-Weekly Oral Gastric-Resident Capsules represents a significant technological breakthrough aimed at closing the gap between daily oral compliance and invasive injectable treatments. This innovation utilizes a novel dosage form that remains in the stomach to release medication steadily over a seven-day span, effectively reducing the pill burden that often hinders treatment success in schizophrenia patients. By sustaining stable plasma levels without requiring injections, this approach tackles adherence issues while respecting patient autonomy. According to the HMP Global Learning Network in June 2025, the article 'Novel Long-Acting Oral Formulation of Risperidone Shows Promise in Phase 3 Trial' reported that the investigational weekly capsule LYN-005 maintained therapeutic concentrations in the STARLYNG-1 study, reaching a geometric mean ratio for minimum concentration of 1.04 at week five relative to daily immediate-release risperidone.

Concurrently, the introduction of Generic Extended-Release Injectables is altering the competitive environment by offering affordable alternatives to long-established branded microsphere products. The approval and release of complex generic variants of standard long-acting antipsychotics are breaking the market exclusivity once enjoyed by originator drugs, leading to substantial price reductions and broader access for payers and patients. This transition compels branded manufacturers to focus on newer delivery technologies, while generics seize market share in the mature injectable sector. For instance, Lupin Limited announced in November 2025, within its 'Lupin Launches Generic Risperidone Extended-Release Injectable Suspension' report, that it had released its generic option in the United States, aiming for a total annual addressable market valued at roughly $187 million.

Key Market Players

  • Otsuka Pharmaceutical Co., Ltd
  • AbbVie Inc
  • Dr. Reddy's Laboratories Ltd
  • Pfizer Inc
  • Endo International plc
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Viatris Inc
  • Novartis AG
  • Lupin Limited

Report Scope

In this report, the Global Risperidone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Risperidone Market, By Route Of Administration

  • Injectable
  • Oral
  • Parenteral

Risperidone Market, By Application

  • Schizophrenia
  • Bipolar Disorder
  • Irritability Associated with Autistic Disorder
  • Others

Risperidone Market, By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

Risperidone Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Risperidone Market.

Available Customizations:

Global Risperidone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Risperidone Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route Of Administration (Injectable, Oral, Parenteral)
    • 5.2.2. By Application (Schizophrenia, Bipolar Disorder, Irritability Associated with Autistic Disorder, Others)
    • 5.2.3. By End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Risperidone Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route Of Administration
    • 6.2.2. By Application
    • 6.2.3. By End-Users
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Risperidone Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route Of Administration
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-Users
    • 6.3.2. Canada Risperidone Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route Of Administration
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-Users
    • 6.3.3. Mexico Risperidone Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route Of Administration
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-Users

7. Europe Risperidone Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route Of Administration
    • 7.2.2. By Application
    • 7.2.3. By End-Users
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Risperidone Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route Of Administration
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-Users
    • 7.3.2. France Risperidone Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route Of Administration
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-Users
    • 7.3.3. United Kingdom Risperidone Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route Of Administration
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-Users
    • 7.3.4. Italy Risperidone Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route Of Administration
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-Users
    • 7.3.5. Spain Risperidone Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route Of Administration
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-Users

8. Asia Pacific Risperidone Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route Of Administration
    • 8.2.2. By Application
    • 8.2.3. By End-Users
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Risperidone Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route Of Administration
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-Users
    • 8.3.2. India Risperidone Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route Of Administration
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-Users
    • 8.3.3. Japan Risperidone Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route Of Administration
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-Users
    • 8.3.4. South Korea Risperidone Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route Of Administration
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-Users
    • 8.3.5. Australia Risperidone Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route Of Administration
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-Users

9. Middle East & Africa Risperidone Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route Of Administration
    • 9.2.2. By Application
    • 9.2.3. By End-Users
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Risperidone Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route Of Administration
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-Users
    • 9.3.2. UAE Risperidone Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route Of Administration
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-Users
    • 9.3.3. South Africa Risperidone Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route Of Administration
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-Users

10. South America Risperidone Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route Of Administration
    • 10.2.2. By Application
    • 10.2.3. By End-Users
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Risperidone Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route Of Administration
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-Users
    • 10.3.2. Colombia Risperidone Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route Of Administration
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-Users
    • 10.3.3. Argentina Risperidone Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route Of Administration
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-Users

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Risperidone Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Otsuka Pharmaceutical Co., Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AbbVie Inc
  • 15.3. Dr. Reddy's Laboratories Ltd
  • 15.4. Pfizer Inc
  • 15.5. Endo International plc
  • 15.6. Teva Pharmaceutical Industries Ltd
  • 15.7. Sun Pharmaceutical Industries Ltd
  • 15.8. Viatris Inc
  • 15.9. Novartis AG
  • 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer